Sensorion Enrolls Last Patient in Clinical Trial of Drug to Prevent Cisplatin-Induced Ototoxicity
Sensorion has completed patient enrollment for its Phase 2a NOTOXIS trial, evaluating SENS-401’s potential to prevent Cisplatin-induced ototoxicity.
Tag: SENS-401
All
Latest
All
Latest
Sensorion Receives Approval for Additional Military Sites in Phase 2 Drug Study
The new centers will recruit volunteer military personnel exposed to impulse noise during their professional activities and suffering from hearing loss.
All
Latest
Sensorion Partners with Institut Pasteur on Research Framework Targeting Hearing Loss
Sensorion and Institut Pasteur have leveraged the last six months to reach a partnership framework agreement. This agreement provides for, after completion of a research program, an exclusive option to obtain licenses.
Sensorion Announces USD $1.9 Million Placement with Cochlear
Sensorion will principally use the funds to finance the preclinical combination studies that will evaluate SENS-401’s therapeutic effect on hearing outcomes achieved with Cochlear’s implantable devices.
Read More
Sensorion and Cochlear Announce Strategic Collaboration for Patients with Cochlear Implants
The collaboration will evaluate therapeutic approaches using SENS-401—R-azasetron besylate, a drug candidate that aims to protect and preserve inner ear tissue when lesions are present that can cause progressive or sequelar hearing impediments—in combination with cochlear implants.
Read More
Sensorion Receives Orphan Drug Designation for Chemotherapy-Induced, Hearing Loss Treatment
The drug is a therapy in development for the treatment of hearing disorders, for the prevention of Platinum-Induced Ototoxicity in pediatric patients.
Read More